

## ARTICLE

Received 13 Mar 2014 | Accepted 21 Aug 2014 | Published 1 Oct 2014

DOI: 10.1038/ncomms6054

# Haematopoietic focal adhesion kinase deficiency alters haematopoietic homeostasis to drive tumour metastasis

Silvia Batista<sup>1</sup>, Eleni Maniati<sup>2,\*</sup>, Louise E. Reynolds<sup>1,\*</sup>, Bernardo Tavora<sup>1</sup>, Delphine M. Lees<sup>1</sup>, Isabelle Fernandez<sup>1</sup>, George Elia<sup>1</sup>, Oriol Casanovas<sup>3</sup>, Cristina Lo Celso<sup>4</sup>, Thorsten Hagemann<sup>2</sup> & Kairbaan Hodivala-Dilke<sup>1</sup>

Metastasis is the main cause of cancer-related death and thus understanding the molecular and cellular mechanisms underlying this process is critical. Here, our data demonstrate, contrary to established dogma, that loss of haematopoietic-derived focal adhesion kinase (FAK) is sufficient to enhance tumour metastasis. Using both experimental and spontaneous metastasis models, we show that genetic ablation of haematopoietic FAK does not affect primary tumour growth but enhances the incidence of metastasis significantly. At a molecular level, haematopoietic FAK deletion results in an increase in PU-1 levels and decrease in GATA-1 levels causing a shift of hematopoietic homeostasis towards a myeloid commitment. The subsequent increase in circulating granulocyte number, with an increase in serum CXCL12 and granulocyte CXCR4 levels, was required for augmented metastasis in mice lacking haematopoietic FAK. Overall our findings provide a mechanism by which haematopoietic FAK controls cancer metastasis.

NATURE COMMUNICATIONS | 5:5054 | DOI: 10.1038/ncomms6054 | www.nature.com/naturecommunications

<sup>&</sup>lt;sup>1</sup>Centre for Tumour Biology, Barts Cancer Institute—a Cancer Research UK Centre of Excellence, Queen Mary, University of London, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, UK. <sup>2</sup> Centre for Cancer and Inflammation, Barts Cancer Institute—a Cancer Research UK Centre of Excellence, Queen Mary, University of London, John Vane Science Centre, Charterhouse Square, London EC1M 6BQ, UK. <sup>3</sup> Translational Research Laboratory, Catalan Institute of Oncology, IDIBELL, 08907 L'Hospitalet de Llobregat, Spain. <sup>4</sup> Department of Life Sciences, Sir Alexander Fleming building, Imperial College, London SW72AZ, UK. \* These authors contributed equally to this work. Correspondence and requests for materials should be addressed to S.B. (email: s.batista@qmul.ac.uk) or to K.H.-D. (email: K.Hodivala-dilke@qmul.ac.uk).

nderstanding the molecular and cellular basis of metastasis still remains a major challenge in current cancer research. Focal adhesion kinase (FAK) is a cytoplasmic protein-tyrosine kinase that localizes mainly at focal adhesion sites, and is one of the central players in integrin and growth factor receptor mediated signalling<sup>1,2</sup>. FAK also has important non-kinase functions<sup>3</sup>. FAK is overexpressed in many human cancer cells and has thus emerged as an anticancer target<sup>4-8</sup>. This has led to the development of FAK inhibitors although off-target effects are apparent<sup>9-11</sup>. Moreover, evidence suggests that FAK may have pleiotropic effects and some work has pointed to FAK being a negative regulator of metastasis. For example, a study of cervical cancer has shown that even though FAK expression was found to be upregulated in tumour cells when compared with normal cervical epithelium, weak FAK expression was significantly correlated with poor overall survival<sup>12</sup>. In addition, Zheng et al.<sup>13</sup> have suggested that FAK-dephosphorylation in tumour cells is important for Ras-mediated metastasis. These data suggest that FAK may not be required for metastasis and that the precise role for FAK in metastasis may be more complex than initially thought. They also raise the question of the importance of stromal FAK in the metastatic process.

The tumour stromal compariment has been shown to have an important role in metastasis<sup>14-16</sup>. Within the tumour stroma, bone marrow-derived cells, specifically myeloid, have been identified as regulators of tumour invasiveness and implicated in organ-specific tumour metastasis<sup>17,18</sup>. A heterogeneous population of cells that comprises myeloid progenitor cells and immature myeloid cells, also named myeloid-derived suppressor cells (MDSCs), has been correlated with clinical stage and metastatic burden<sup>19,20</sup>. MDSCs are a mixture of myeloid cells with characteristics of monocytes and granulocytes and are generally described by the co-expression of the mouse markers CD11b and Gr1 (CD11b<sup>+</sup>Gr1<sup>+</sup>)<sup>21,22</sup>. Their expansion at metastatic sites generates an immunosuppressive niche that suppresses T cell activation, proliferation and cytotoxicity and also suppresses NK cell cytotoxicity<sup>23–26</sup>. These cells have been shown to facilitate tumour cell seeding and colonization at metastatic sites and are thereby thought to drive metastasis<sup>27–29</sup>.

In short, analysis of tumour cells has suggested that FAK is required for tumour metastasis, but the role of stromal or haematopoietic-derived FAK in this process is poorly understood. We have tested the requirement of haematopoietic FAK in metastasis using genetic ablation approaches in combination with haematopoietic transplant experiments. Here we establish that decreased expression of FAK in the haematopoietic compartment generates a pro-metastatic microenvironment that actually enhances tumour cell colonization and metastasis. Our data highlight a role for haematopoietic FAK as a negative, rather than positive, regulator of tumour cell metastasis via the control of haematopoietic homeostasis and mobilization of CD11b  $^+$  Gr1 $^+$  cells.

#### Results

FAK deletion increases metastases in the *RIP-Tag2* model. A genetic approach was used to ablate FAK globally to study the effect of FAK deletion on tumour metastasis. We generated a tamoxifen-inducible model for FAK deletion in adult mice,  $RERTn^{ERT/ERT}Cre;FAK^{J/fl}$  and confirm efficient FAK deletion at the protein level in this system (Supplementary Figs 1A–D, 2A, B)<sup>30–32</sup>.  $RERTn^{ERT/ERT}Cre$  mice have been used previously to induce global deletion of target genes<sup>31</sup>. Non-induced  $RERTn^{ERT/ERT}Cre;FAK^{J/fl}$  mice were viable and fertile with no obvious defects. The effect of FAK deletion on metastasis was first analysed in *RIP-Tag2* mice, a well-studied, spontaneous model of

pancreatic cancer that expresses the SV40 T antigen (Tag) under the control of the rat insulin promoter<sup>33</sup>. Expression of Tag in pancreatic islet  $\beta$ -cells leads to the development of hyperplastic lesions at 6-8 weeks of age of which a fraction will progress into highly vascularized B-cell tumours at 10-14 weeks of age. These tumours have been reported to invade and spread to lymph nodes and liver<sup>34</sup>. RIP-Tag2 mice die by 16 weeks of age<sup>33</sup>. *RIP-Tag2* mice were crossed with  $RERTn^{ERT/ERT}Cre;FAK^{fl/fl}$ (RERTFAK<sup>KO</sup>) or control  $FAK^{fl/fl}$  (RERTFAK<sup>WT</sup>) mice generating RIP-Tag2;RERTFAK<sup>KO</sup> and RIP-Tag2;RERTFAK<sup>WT</sup> mice respectively. Mice were treated with tamoxifen from 9 weeks of age to induce FAK deletion in both tumour and stromal compartments. Total pancreatic tumour burden was not statistically different between genotypes at 15 weeks of age (Fig. 1a). Pancreatic tumours in RIP-Tag2 mice are classified into three levels of progression: encapsulated, the least aggressive form; invasive type I, where the invasive front of the tumour begins to penetrate into the surrounding pancreas; and invasive type II, where the invasive front of the tumour engulfs islands of normal pancreas<sup>34,35</sup>. Quantification of Tag-positive pancreas sections revealed that FAK deletion had no significant effect on tumour invasiveness (Fig. 1b). Histological analysis of metastases to the peri-pancreatic lymph nodes also showed no statistically significant differences between genotypes in incidence of metastasis or percentage of lymph nodes with metastases (Supplementary Fig. 3A). In contrast the incidence of metastases and number of metastases per liver were significantly higher in RIP-Tag2;RERTFAKKO when compared with RIP-Tag2;RERTFAK<sup>WT</sup> mice (Fig. 1c-e). These data show that when FAK is deleted globally, RIP-Tag2 primary tumour burden is not affected but metastasis is enhanced.

Stromal FAK deficiency increases experimental metastasis. Tumour growth and metastasis is regulated not only by the tumour cells themselves but also by the host or stromal compartment. To dissect the role of FAK within the host or stromal compartment from that in the tumour compartment, an experimental metastasis approach was employed. Syngeneic mouse B16 melanoma cells, which express FAK, were injected via the tail vein into RERTFAK<sup>KO</sup> and RERTFAK<sup>WT</sup> mice. At 19 days post B16 cell injection, significantly elevated numbers of metastatic nodules were observed in several organs including the lungs, liver and bones of RERTFAK<sup>KO</sup> mice when compared with controls (Fig. 2a). Sections of tissues were stained with haematoxylin and eosin and metastases counted. Results showed a significant increase in the total number of metastases in RERTFAK<sup>KO</sup> mice when compared with controls (Fig. 2b-d). These data indicate that loss of FAK in the stromal compartment is sufficient to increase experimental B16 tumour metastasis.

Haematopoietic FAK deletion increases *RIP-Tag2* metastases. Tumour cell survival in the circulation, seeding at distant sites, invasion and dissemination are all processes dependent on the tumour microenvironment. These processes have been shown to involve many cell types but the molecular mechanisms underlying the role of bone marrow-derived cells is still unclear<sup>18,36</sup>. To dissect the requirement of FAK within the haematopoietic compartment from that in the whole stromal compartment, we undertook an adoptive transfer approach. Briefly, lethally irradiated 6-week-old female *RIP-Tag2* mice were transplanted with bone marrow from either male *RERTn*<sup>*ERT/ERT*</sup>*Cre;FAK*<sup>*fl/fl*</sup> or control *FAK*<sup>*ll/fl*</sup> cre negative mice generating RIP-Tag2;BMFAK<sup>KO</sup> and RIP-Tag2;BMFAK<sup>WT</sup> chimeras, respectively. Two weeks after bone marrow transplantation, mice were treated with tamoxifen to induce FAK deletion predominantly in the haematopoietic



**Figure 1 | FAK deficiency enhances metastasis in the** *RIP-Tag2* **model.** RIP-Tag2;RERTFAK<sup>WT</sup> and RIP-Tag2;RERTFAK<sup>KO</sup> mice started tamoxifen treatment at 9 weeks of age and were necropsied at 15 weeks of age. Histological analysis was performed in five different depth areas 100 µm apart of pancreas and liver with immunohistochemical staining for the tumour marker SV40 T antigen (Tag). (a) Primary tumour burden in RIP-Tag2;RERTFAK<sup>WT</sup> and RIP-Tag2;RERTFAK<sup>KO</sup> mice. Bar chart represents the total macroscopic tumour burden + s.e.m., n = 10-13 mice per genotype. Representative images of Tag immunostained sections primary tumours are shown. NS, not statistically significant, Student's *t*-test. (b) Histological images of Tag immunostained tumour sections at different stages of invasiveness are shown. Quantification of tumour invasiveness is presented as the percentage of encapsulated islet tumours (encapsulated), microinvasive carcinomas (invasive type I), and fully invasive carcinomas (invasive type II) in RIP-Tag2;RERTFAK<sup>WT</sup> and RIP-Tag2;RERTFAK<sup>KO</sup> mice. NS, not statistically significant, Mann-Whitney test. (c) Representative images of Tag-positive liver metastases. Bar charts represent (d) incidence of metastasis to the liver or (e) number of metastases per liver. Scale bars, (a) 500 µm, (b) 200 µm, (c)50 µm. \**P*<0.05; \*\**P*<0.01; Mann-Whitney test.

compartment. At 16 weeks of age, necropsies were performed and showed that RIP-Tag2;BMFAK $^{\rm KO}$  mice had no significant difference in pancreatic tumour burden when compared with RIP-Tag2;BMFAKWT controls (Fig. 3a). It is noteworthy that tumour burden in both genotypes was lower than predicted for RIP-Tag2 mice at this age most likely because the animals were irradiated, as reported previously37. Quantification of Tag immunostained pancreas sections revealed that haematopoietic FAK deletion had no significant effect on tumour invasiveness (Fig. 3b) suggesting that haematopoietic FAK is not sufficient to modulate primary tumour growth or invasion per se. Histological analysis of metastases to the peri-pancreatic lymph nodes showed very low numbers of lymph node metastases in both genotypes and no statistically significant differences between them (Supplementary Fig. 3B). Despite this, the incidence of liver metastasis was significantly higher in RIP-Tag2;BMFAK<sup>KO</sup> when compared with RIP-Tag2;BMFAKWT mice (Fig. 3c,d). Unexpectedly, RIP-Tag2;BMFAKKO mice also presented an increased incidence of lung metastases, an organ that has not been previously reported to display RIP-Tag2 metastasis (Fig. 3c,d). The overall incidence of metastasis was statistically increased in RIP-Tag2;BMFAKKO mice when compared with RIP-Tag2;BMFAK<sup>WT</sup> controls

(Fig. 3d). These data from a spontaneous model of cancer show that deficiency of haematopoietic FAK is sufficient to enhance tumour metastasis.

Haematopoietic FAK deletion increases B16 metastases. We next tested the effect of haematopoietic FAK deficiency on experimental tumour metastasis by injecting B16 mouse melanoma tumour cells in the tail vein of BMFAKWT and BMFAKKO mice. Results showed that deficiency of FAK in the haematopoietic compartment alone was sufficient to increase the number of tumour metastases in BMFAK<sup>KO</sup> mice significantly when compared with controls (Fig. 4a). The presence of this increased number of metastases was confirmed by histological analysis of the lungs, liver and bones from BMFAKKO mice and respective controls (Fig. 4b). Quantification revealed a significant increase in the number of B16 nodules not only in BMFAK<sup>KO</sup> lungs, but also in the livers and bones of these mice when compared with controls (Fig. 4c,d). Validation of the adoptive transfer approach is given in Supplementary Figs 2C and 4. Together, these data indicate that the loss of stromal FAK, solely within the haematopoietic compartment, is sufficient to control tumour metastasis.



**Figure 2 | Loss of stromal FAK increases experimental metastasis.** RERTFAK<sup>WT</sup> and RERTFAK<sup>KO</sup> mice were injected via the tail vein with B16 mouse melanoma tumour cells and analysed 19 days post inoculation. Metastases in lungs, liver and bones of RERTFAK<sup>WT</sup> and RERTFAK<sup>KO</sup> mice: (a) Macroscopic images and (b) representative images of haematoxylin and eosin stained sections. (c) Bar chart represents the mean number of metastases per mouse + s.e.m. (d) Bar charts show mean number of metastases to the lung, liver or bone + s.e.m., n = 10-12 mice per genotype. BM, bone marrow; CB, calcified bone; Met, metastases; white arrow, metastases. Scale bars, (a) 1cm; (b) 200 µm. \*P < 0.05; \*\*P < 0.01, Mann-Whitney test.

A recent paper by Catena et al.<sup>38</sup> showed that expression of thrombospondin-1 (Tsp-1) by Cd11b<sup>+</sup>Gr1<sup>+</sup> cells generates a metastatic refractory microenvironment. In line with this study we have observed lower levels of Tsp-1 in bone marrow from RERTFAK<sup>KO</sup> animals that show increased numbers of metastases (Supplementary Figs 5A and 6A). In the same study, tumours cells that secrete prosaposin (Psap) induce Tsp-1 expression in CD11b<sup>+</sup>Gr1<sup>+</sup> cells causing them to behave as metastasis refractory cells<sup>38</sup>. To assess the relevance of prosaposin in our system, we first analysed prosaposin levels in B16F0 and B16F10 tumour cells used in our study. Both B16F0 and B16F10 showed no detectable levels of prosaposin and we saw no effect of introducing prosaposin in the phenotypes observed in BMFAK<sup>KO</sup> mice; thus we conclude that, for the purposes of our experiments, prosaposin is unlikely to be involved (Supplementary Figs 5B-D and 6B–C).

FAK deficiency shifts HSCs towards a myeloid commitment. Our results suggest that metastasis is enhanced in mice lacking haematopoietic FAK. It is conceivable that loss of FAK could be compensated for by the upregulation of other functionally related molecules. Pyk2 is a member of the FAK family of tyrosine kinases and has been shown to compensate for FAK loss in previous studies<sup>39–41</sup>. Western blot analysis of haematopoietic

lysates from RERTFAK<sup>KO</sup> and RERTFAK<sup>WT</sup> mice showed no significant changes in the levels of Pyk2 between genotypes (Supplementary Fig. 7). In addition the expression levels of other focal contact proteins such as paxillin, vinculin and talin were also unchanged between RERTFAK<sup>KO</sup> and RERTFAK<sup>WT</sup> samples (Supplementary Figs 2D and 7). These data suggest that at least these candidate genes were unlikely to be compensating for the loss of FAK.

To understand the mechanism that drives the increased metastasis in the absence of FAK we sought to phenotypically characterize the haematopoietic compartment of RERTFAK<sup>WT</sup> and RERTFAK<sup>KO</sup> mice. The role of bone marrow-derived cells in tumour progression and metastasis has been studied extensively, but the role of FAK in this process is not known<sup>18,29,36</sup>. Recent evidence has suggested that FAK can regulate haematopoietic homeostasis in the bone marrow<sup>42</sup>. Using flow cytometric analysis we have characterized haematopoietic stem cells (HSCs) and committed progenitors in bone marrow from RERTFAKWT and RERTFAK<sup>KO</sup> mice (Fig. 5a). We observed an increase in phenotypically defined long-term repopulating stem cells LT-HSCs (Lin<sup>low</sup> c-kit + Sca-1 + CD34 - Flk-2 -) in RERTFAKKO mice when compared with RERTFAK<sup>WT</sup> control mice with only a tendency for an increase in short-term repopulating stem cells ST-HSCs (Lin<sup>low</sup> c-kit<sup>+</sup> Sca-1<sup>+</sup> CD34<sup>+</sup> Flk-2<sup>-</sup>; Fig. 5b,c). No differences were observed in multipotent progenitors MPP (Linlow c-kit+ Sca-1+



**Figure 3** | **Haematopoietic FAK deficiency enhances** *RIP-Tag2* **metastases.** *RIP-Tag2* mice were transplanted at 6 weeks of age, and tamoxifen treated 2-3 weeks thereafter generating RIP-Tag2;BMFAK<sup>WT</sup> and RIP-Tag2;BMFAK<sup>KO</sup> chimeras. Mice were necropsied at 16 weeks of age. Histological analysis was performed in six different depth areas 100  $\mu$ m apart of pancreas, liver and lungs with immunohistochemical staining for the tumour marker SV40 T antigen (Tag). (a) Tumour burden in RIP-Tag2;BMFAK<sup>WT</sup> and RIP-Tag2;BMFAK<sup>KO</sup> mice. Bar chart represents the proportion of tumour burden as a % of tumour area per animal normalized to total pancreas area + s.e.m., n = 7-13 mice per genotype. NS, not statistically significant, Mann-Whitney test. (b) Quantification of tumour invasiveness is presented as the percentage of encapsulated islet tumours (encapsulated), microinvasive carcinomas (invasive type I), and fully invasive carcinomas (invasive type II) in RIP-Tag2;BMFAK<sup>WT</sup> and RIP-Tag2;BMFAK<sup>KO</sup> mice. NS, not statistically significant, Mann-Whitney test. Scale bar, 200  $\mu$ m. (c) Representative images of Tag immunostained sections of liver and lung. Metastases to liver and lungs are shown. Scale bar, 50  $\mu$ m. (d) Bar charts represent incidence of metastasis to either liver or lung or total percentage of animals with metastases. <sup>†</sup>*P* < 0.058; \**P* < 0.01, Mann-Whitney test.

CD34<sup>+</sup> Flk-2<sup>+</sup>; Supplementary Fig. 8A). Analysis of bone marrowcommitted progenitors shows an increase in common myeloid progenitor CMP (Lin<sup>low</sup> c-kit<sup>+</sup> Sca-1<sup>-</sup> CD34<sup>+</sup> CD16/32<sup>mid</sup>) in RERTFAK<sup>KO</sup> when compared with RERTFAK<sup>WT</sup> mice (Fig. 5d). No differences in other bone marrow-committed progenitors, such as common lymphoid progenitor CLP (Linlow c-kitmid Sca-1mid CD127<sup>+</sup>), granulocyte-monocyte progenitor GMP (Lin<sup>low</sup> c-kit<sup>+</sup> Sca-1<sup>-</sup> CD34<sup>+</sup> CD16/32<sup>bright</sup>) or megakaryocyte and erythroid progenitors MEP (Lin<sup>low</sup> c-kit + Sca-1 - CD34 + CD16/32<sup>low</sup>) were observed between genotypes (Supplementary Fig. 8B-D)43. These data suggest that FAK-deficient HSCs are predisposed to a myeloid commitment. To test this hypothesis, we sorted HSCs (Lin<sup>low</sup> c-kit Sca-1<sup>+</sup>) from the bone marrow of RERTFAK<sup>WT</sup> and RERTFAK<sup>KO</sup> mice and analysed transcription factors involved in myeloid commitment by real time PCR. PU.1 is a transcription factor critically responsible for the activation of myeloid-specific promoters, such as murine neutrophil elastase, granulocyte colony stimulating factor (G-CSF), macrophage (M)-CSF and GM-CSF promoters<sup>44,45</sup>. On the other hand, GATA-1 expression has been shown to suppress the myeloid expression program<sup>46,47</sup>. FAK<sup>KO</sup> HSCs had increased PU.1 and decreased GATA-1 expression, when compared with controls. (Fig. 5e-g). Together these data show that FAK deletion shifts HSC transcriptional programme towards myeloid lineage commitment.

Loss of BM FAK induces a pro-metastatic microenvironment. Granulocytes or polymorphonuclear cells (CD11b<sup>+</sup> Gr1<sup>hi</sup>Lv6C<sup>lo+int</sup>—PMN) have a short half-life, are quickly mobilized into the circulation and are considered the best indicator of changes in haematopoietic homeostasis<sup>48,49</sup>. The increase in common myeloid progenitor was reflected in the periphery by elevated numbers of PMN cells in the blood and spleen of RERTFAK<sup>KO</sup> mice in the steady state and at various stages after tail vein injection of tumour cells. Increased numbers of granulocytes were observed in the blood (Fig. 6a) and spleen (Fig. 6b) of unchallenged RERTFAK<sup>KO</sup> mice, 2–5 h after tumour cell injection (time for tumour cell homing), 24 h after tumour cell injection (time for tumour cell colonization) and at the experimental end point (time of tumour cell establishment). We also observed similar changes in the monocytic fraction of CD11b<sup>+</sup>Gr1<sup>+</sup> cells (CD11b<sup>+</sup>Gr1<sup>lo+int</sup>Ly6C<sup>hi</sup>—Mon) but to a lesser extent (Supplementary Fig. 8E-G). Our data establish that loss of haematopoietic FAK alters haematopoietic homeostasis and increases CD11b+Gr1+ cell mobilization and numbers into the circulation.

Given the increased mobilization and expansion of the  $CD11b^+Gr1^+$  cells in the blood and spleen at early time points after tumour cell injection, we next analysed whether an increase of these cells was observed at metastatic sites such as the lung.



**Figure 4 | Haematopoietic FAK deletion increases B16 metastasis.** BMFAK<sup>WT</sup> and BMFAK<sup>KO</sup> mice were injected with B16 mouse melanoma tumour cells via the tail vein in experimental metastasis experiments and analysed 15–17 days post tumour cell injection. Metastases in lungs, liver and bones from BMFAK<sup>WT</sup> and BMFAK<sup>KO</sup> mice: (a) Macroscopic images and (b) representative images of haematoxylin and eosin stained sections. (c) Bar chart shows mean number of metastases per mouse, + s.e.m. (d) Bar charts show mean number of metastases to the lung, liver and bone + s.e.m., n = 9 mice per genotype. BM, bone marrow; CB, calcified bone; Met, metastases; white arrow, metastases. Scale bars, (a) 1 cm; (b) 200 µm. \**P*<0.05; \*\**P*<0.01, Mann-Whitney test.

Immunofluorescence for Gr1 showed increased numbers of Gr1<sup>+</sup> cells in the lungs of RERTFAK<sup>KO</sup> and BMFAK<sup>KO</sup> mice, 2–5 h post tumour cell injection, when compared with RERTFAK<sup>WT</sup> and BMFAK<sup>WT</sup> controls, respectively (Fig. 6c,d). An increased number of Gr1<sup>+</sup> cells has been correlated previously with enhanced metastasis<sup>27–29</sup>. In parallel we noted a decrease in infiltration of CD4<sup>+</sup> and CD8<sup>+</sup> T cells at early time points after tumour cell injection (Supplementary Fig. 9A–D), but no differences in NK cell infiltrate in the lungs of RERTFAK<sup>KO</sup> or BMFAK<sup>KO</sup> mice when compared with controls (Supplementary Fig. 9E, F). Since no changes in CLP were observed in the bone marrow (Supplementary Fig. 8B), it is possible that these T cell changes are a consequence of the increased Gr1<sup>+</sup> cell numbers as the latter have been shown previously to have immune suppressive properties<sup>23,24</sup>.

Metastasis and neutrophil recruitment are dependent on complex cytokine networks. Analysis of serum cytokine levels after tumour cell injection by protein cytokine arrays showed increased levels of CXCL12 in the serum of RERTFAK<sup>KO</sup> mice (Fig. 6e). This coincided with a significant increase in CXCR4 mRNA levels in FAK<sup>KO</sup> PMNs recruited to the lung after tumour cell injection (Fig. 6f,g). CXCL12-CXCR4 axis is involved in metastasis and neutrophil homing<sup>25,50,51</sup>. The higher levels of CXCR4 expression in FAK<sup>KO</sup> PMN cells suggest that these cells may have increased propensity to respond to pro-metastatic cytokines such as CXCL12 and home to sites of metastasis. In addition, other inflammatory cytokines such as the complement component

C5/C5a was found increased in the serum of RERTFAK<sup>KO</sup> mice (Supplementary Fig. 9G). C5/C5a has previously been shown to be involved in neutrophil recruitment and lung inflammation preceding lung metastasis<sup>52,53</sup>. Taken together these data suggest RERTFAK<sup>KO</sup> mice present a microenvironment that favours the recruitment of PMN to metastatic sites.

Gr1 cells govern tumour cell colonization in RERTFAKKO mice. FAK deficiency in the haematopoietic compartment resulted in changes in the inflammatory microenvironment that facilitated recruitment of PMN to metastatic sites at early time points after tumour cell injection. To test whether these changes could have an impact on tumour cell homing or colonization, key steps in metastasis, red cell tracker-labelled tumour cells were injected into the tail vein of RERTFAK<sup>WT</sup>, RERTFAK<sup>KO</sup>, BMFAK<sup>WT</sup> and BMFAK<sup>KO</sup> mice and lungs harvested 2–5 h (to test for homing) and 48 h (to test for colonization) thereafter. Although there were no differences in the numbers of tumour cells homing in the lungs 2-5 h post injection, a significant increase in tumour cell colonization at 48 h post injection was observed in RERTFAKKO and BMFAKKO mice when compared with RERTFAKWT and BMFAK<sup>WT</sup> controls (Fig. 7a,b). Analysis of Ki67 showed that the majority of cells were not proliferating at 48 h post injection and there were no differences between RERTFAKWT and RERTFAKKO mice, suggesting FAK deletion affected the seeding of tumour cells rather than proliferation (Supplementary Fig. 10A).



**Figure 5 | FAK deficiency shifts HSCs towards a myeloid commitment.** Single-cell suspensions of bone marrow from RERTFAK<sup>WT</sup> and RERTFAK<sup>KO</sup> mice were analysed by flow cytometry. (**a**) Long-term bone marrow-derived haematopoietic stem cells, LT-HSC (Lin<sup>low</sup> c-kit<sup>+</sup> Sca-1<sup>+</sup> CD34<sup>-</sup> Flk-2<sup>-</sup>), short-term bone marrow-derived haematopoietic stem cells, ST-HSC (Lin<sup>low</sup> c-kit<sup>+</sup> Sca-1<sup>+</sup> CD34<sup>+</sup> Flk-2<sup>-</sup>) and common myeloid progenitors, CMP (Lin<sup>low</sup> c-kit<sup>+</sup> Sca-1<sup>-</sup> CD34<sup>+</sup> CD16/32<sup>mid</sup>) in the BM of RERTFAK<sup>WT</sup> and RERTFAK<sup>KO</sup> mice were compared. Representative dot blots are shown. Bar charts show fold change of bone marrow LT-HSC (**b**) ST-HSC (**c**) and CMP (**d**) + s.e.m., n = 10-13 mice per genotype. (**e-g**) HSCs (Lin<sup>low</sup> c-kit<sup>+</sup> Sca-1<sup>+</sup>) were sorted from the bone marrow of RERTFAK<sup>WT</sup> and RERTFAK<sup>KO</sup> mice, RNA extracted and reversed transcribed into cDNA. Bar charts show mean (**e**) *FAK*, (**f**) *PU.1* and (**g**) *GATA-1* mRNA levels + s.e.m. quantified by real time PCR, n = 3-4 mice/genotype. \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001, Student's t-test.

To examine the direct requirement of Gr1  $^+$  cells in tumour cell colonization, RERTFAK  $^{\rm WT}$  and RERTFAK  $^{\rm KO}$  mice were given two doses of a Gr1-blocking antibody (RB6-8C5), to deplete Gr1<sup>+</sup> cells one day before and on the day of B16 melanoma cell injection via the tail vein. An isotype-matched antibody was used as a negative control. Efficient depletion of Gr1<sup>+</sup> cells was confirmed at 2-5 and 48 h post tumour cell injection (Supplementary Fig. 10B). The control antibody treatment had no effect on the increased colonization observed previously in RERTFAK<sup>KO</sup> mice when compared with RERTFAK<sup>WT</sup> controls. Gr1<sup>+</sup> cell depletion had small effect in RERTFAK<sup>WT</sup> animals but, however, had decreased tumour cell colonization in RERTFAKKO mice (Fig. 7c,d). These data suggest that the elevated number of Gr1<sup>+</sup> cells in mice lacking stromal FAK is a critical regulator of the elevated tumour metastasis observed. In addition, RERTFAKWT and RERTFAK<sup>KO</sup> mice were given a Cxcr4 inhibitor AMD3100 or phosphate-buffered saline (PBS) as a control on the day of B16 melanoma cell injection via the tail vein. Cxcr4 inhibition was sufficient to decrease blood granulocyte levels soon after tumour cell injection (Fig. 7e). Importantly Cxcr4 inhibition had no effect in RERTFAK<sup>WT</sup> but decreased RERTFAK<sup>KO</sup> tumour cell colonization (Fig. 7c,f). Together these data suggest that Gr1 cell numbers and Cxcr4 signalling are important drivers for the increased tumour cell colonization observed in the absence of stromal FAK.

#### Discussion

Here we show that loss of FAK in the haematopoietic compartment is sufficient to augment metastasis. This is unexpected and highlights a mechanism by which metastasis is regulated.

The overexpression of FAK in cancer cells, combined with it essential role in cell migration, has implicated this molecule as a positive regulator of cancer progression<sup>5,54,55</sup>. High levels of both FAK and Src can be indicative of poor prognosis and tumour recurrence in a variety of cancers<sup>5</sup> and these data have been interpreted to suggest that inhibitors of FAK may control cancer growth and progression. Indeed several reports have shown that inhibition of FAK, often in combination with the inhibition of other targets, can suppress tumour growth and metastasis<sup>9-11</sup>. In contrast, possible negative roles for FAK in tumour progression have also been reported<sup>12,13</sup>. For example, FAK expression is not a prognostic marker for colon adenocarcinoma patients and FAK expression does not correlate with survival<sup>56</sup>; loss of tumour FAK is actually associated with increased metastasis in cervical cancer<sup>12</sup>; pharmacological inhibition of Src can suppress metastasis without affecting FAK activation<sup>57</sup>; and under some oncogenic conditions, such as those initiated by Ras, metastasis is promoted by dephosphorylating FAK<sup>13</sup>.

Although various mechanisms have been discussed to explain how tumour cell FAK might control metastasis, what was not known was whether the absence of FAK in the stromal, and especially in the haematopoietic compartment, has any impact on metastasis. In contrast to previous data examining the tumour cell compartment, using a genetic ablation approach our data show that loss of stromal, and in particular, haematopoietic FAK is sufficient to actually enhance tumour metastasis. This implies that we may need to change our concept of FAK to reflect its potentially counteractive and pleiotropic roles during metastasis. In addition, although haematopoietic FAK deficiency was sufficient to increase metastatic burden, it did not affect primary



**Figure 6 | Stromal FAK deficiency induces PMN changes.** Single-cell suspensions of (**a**) blood and (**b**) spleen from RERTFAK<sup>WT</sup> and RERTFAK<sup>KO</sup> mice that were either unchallenged or 2-5 h, 24 h and 15 days post tumour cell injection via the tail vein were analysed by flow cytometry. Bar charts show numbers of CD45<sup>+</sup> CD11b<sup>+</sup> Gr1<sup>hi</sup>Ly6C<sup>lo</sup> (PMN) in blood and spleen from RERTFAK<sup>WT</sup> and RERTFAK<sup>KO</sup> mice. n = 3-4 mice per genotype. (**c**,**d**) B16 tumour cells, previously labelled with red cell tracker CMTPX, were injected via the tail vein into RERTFAK<sup>WT</sup>, RERTFAK<sup>KO</sup>, BMFAK<sup>WT</sup> and BMFAK<sup>KO</sup> mice. Then 2-5 h post injection, lungs were processed and sections immunostained for Gr1<sup>+</sup> cells. (**c**) Representative images of B16 tumour cells (red) and Gr1<sup>+</sup> cells (green) in RERTFAK<sup>WT</sup>, RERTFAK<sup>KO</sup>, BMFAK<sup>WT</sup> and BMFAK<sup>KO</sup> mice. Bar charts represent number of Gr1<sup>+</sup> cell per mm<sup>2</sup> of lung section + s.e.m., n = 4-5 mice per genotype. (**e**) Serum levels of CXCL12 in RERTFAK<sup>WT</sup> and RERTFAK<sup>KO</sup> mice 24 h after tumour cell injection. Bar chart represents fold change relative to RERTFAK<sup>WT</sup> + s.e.m. (**f**,**g**) CD45<sup>+</sup> CD11b<sup>+</sup> Gr1<sup>hi</sup>Ly6C<sup>lo</sup> (PMN) cells were sorted from the lung of BMFAK<sup>WT</sup> and BMFAK<sup>KO</sup> mice 24 h after tumour cell injection. RNA levels + s.e.m. quantified by real time PCR, n = 8-10 mice per genotype. Scale bar, 100 µm. NS, not statistically significant; \*P < 0.05; \*\*P < 0.01; \*\*\*P < 0.001, Student's t-test.

tumour size or invasiveness suggesting that this initial step of tumorigenesis is not dependent on haematopoietic FAK. Furthermore, our data also show that genetic ablation of FAK in both the stromal and cancer compartments simultaneously also results in enhanced metastasis suggesting that loss of FAK globally is not sufficient to reduce metastasis.

Our data imply that haematopoietic FAK acts as a negative regulator of metastatic dissemination and raise the question of which cells are responsible for this phenotype. Haematopoietic homeostasis is dependent on HSCs that have the ability to self renew and maintain lineage differentiation potential<sup>58,59</sup> and it has been hypothesized that disrupting interactions between HSCs and bone marrow stroma affects HSC fate<sup>60–62</sup>. Here, we observed that the absence of stromal FAK induced an increase in numbers of LT-HSCs and CMP within the bone marrow. Importantly FAK<sup>KO</sup> HSCs present higher levels of the transcription



**Figure 7 | Gr1 cells govern tumour cell colonization in RERTFAK<sup>KO</sup> mice.** B16 tumour cells, previously labelled with red cell tracker CMTPX, were injected via the tail vein into RERTFAK<sup>KO</sup>, RERTFAK<sup>KO</sup>, BMFAK<sup>WT</sup> and BMFAK<sup>KO</sup> mice. (a) Lungs were harvested 2-5 h and 48 h after tumour cell injection to measure the numbers of tumour cells homing and colonizing in the lungs, respectively. Representative stereomicroscopic images of lung surfaces from RERTFAK<sup>WT</sup> and RERTFAK<sup>KO</sup> mice are given. (b) Bar charts represent mean number of B16 cells mm<sup>-2</sup> lung section + s.e.m., n = 5 mice per genotype. (c) Gr1 antibody-depletion of Gr1 + cells or CXCR4 inhibition with AMD3100 in RERTFAK<sup>WT</sup> and RERTFAK<sup>KO</sup> mice. Nonspecific lgG or PBS were used as a control. Mice were then injected with red cell tracker CMTPX labelled B16 cells. Representative stereomicroscope images of fresh lungs from both genotypes are given. (d) Bar chart shows fold change relative to lgG of mean number of B16 cells per lung area. n = 10-12 mice per test. (e) Single-cell suspensions of blood from RERTFAK<sup>WT</sup> and RERTFAK<sup>KO</sup> mice 2 h post tumour cell injection via the tail vein were analysed by flow cytometry. Bar charts show numbers of CD45 + CD11b + Gr1<sup>hi</sup>Ly6C<sup>lo</sup> (PMN) in blood. n = 3-4 mice per genotype. (f) CXCR4 inhibition with AMD3100 effect in B16 colonization to the lungs of RERTFAK<sup>WT</sup> and RERTFAK<sup>KO</sup> mice. Bar chart shows fold change relative to PBS of mean number of B16 cells per lung area. n = 10-16 mice per test. Scale bar, (a,c) 500 µm. NS, not statistically significant; \*P < 0.05; \*\*\*P < 0.001, Student's t-test.

factor *PU.1* and lower levels of *GATA-1*—both hallmarks of commitment to a myeloid lineage<sup>44-47</sup>. Interestingly FAK has been shown to regulate other GATA family transcription factors<sup>63</sup>. This shift towards myeloid lineage commitment did not correlate with compensation within the bone marrow by Pyk2, or other focal contact proteins such as vinculin, paxillin or talin. Instead, our data established that loss of haematopoietic FAK can deregulate the HSC niche, an observation that is

supported by recently published work demonstrating that FAK is preferentially expressed in HSCs and that loss of bone marrow FAK in Mx1-Cre;FAKfl/fl mice induced an increase in activated HSCs<sup>42</sup>. More importantly, our present data identifies a role for haematopoietic FAK in controlling myeloid lineage commitment programme and raised the question of whether this could be the main driver of the tumour metastasis observed.

The changes in haematopoietic homeostasis that resulted in increased CMP levels were reflected in the periphery by increased mobilization of granulocytes into the circulation as described before<sup>48,49</sup>. Increased numbers of granulocytic and monocytic CD11b<sup>+</sup>Gr1<sup>+</sup> cells were observed in the blood and spleen of tumour-initiated RERTFAK<sup>KO</sup> mice when compared with controls. Overall our findings establish that haematopoietic FAK is important for the regulation of circulating myeloid cell numbers, which have been shown to correlate with metastasis burden<sup>19,20</sup>.

Cell changes were also accompanied by significant increases in CXCL12 and C5/C5a in the serum of RERTFAKKO mice, known pro-metastatic cytokines that correlate with poor prognosis<sup>50,53</sup>. Increase in CXCL12 serum levels have been observed in GATA-1<sup>low</sup> mice, a phenotype consistent with the low GATA-1 levels observed in FAK<sup>KO</sup> HSCs<sup>64</sup>. On the other hand, CXCL12 serum increase was accompanied by elevated levels of its receptor CXCR4 in FAK<sup>KO</sup> PMNs sorted from lung after tumour cell injection. CXCR4 is a granulocyte homing receptor so this suggests that stromal FAK deficiency induced not only a change in PMN numbers, but also in their function. The high levels of CXCR4 in FAK<sup>KO</sup> PMNs likely increase their propensity to respond to CXCL12 and home to sites of metastasis. Indeed, this has been shown to be one of the mechanisms that governs granulocyte infiltration to drive metastasis<sup>50,51</sup>. Interestingly C5/ C5a has also been demonstrated to induce granulocyte recruitment in inflammatory conditions<sup>65</sup>.

Conversely, analysis of lymphoid numbers within the lung at early time points after tumour cell injection showed a decrease in CD8 and CD4 T cells with no alterations in NK cell numbers in RERTFAK<sup>KO</sup> and BMFAK<sup>KO</sup> mice when compared with respective controls. Since no changes were observed in bone marrow common lymphoid progenitors, this suggested that, in contrast to myeloid cells, the recruitment of T cells to the lung was impaired. Granulocytic and monocytic CD11b+Gr1+ cells are also referred to as MDSCs. MDSCs are characterized by their ability to suppress CD8 and CD4 T cell proliferation and cytotoxicity and suppress NK cell activity, which, together, are thought to enhance metastasis<sup>23,24</sup>. Moreover C5/C5a has been shown not only to increase the infiltration of MDSCs, but also their immune suppressive properties, resulting in decreased infiltration of CD8 T cells in tumours<sup>66</sup>. Our data corroborated these findings and point towards a role for haematopoietic FAK deficiency in increasing not only numbers, but also recruitment of granulocytes to metastatic sites, thus generating a pro-metastatic microenvironment<sup>27–29</sup>. In fact depleting Gr1<sup>+</sup> cells or inhibition of CXCR4 in RERTFAK<sup>WT</sup> and RERTFAK<sup>KO</sup> mice before tumour cell injection was sufficient to reduce tumour cell colonization in the lungs of RERTFAK<sup>KO</sup> mice to levels observed in RERTFAK<sup>WT</sup> control mice. Thus our work shows that loss of stromal FAK, via the upregulation of Gr1<sup>+</sup> cell numbers and CXCR4 signalling, induces a permissive microenvironment at metastatic sites that facilitates the increased colonization by tumour cells observed in RERTFAKKO and BMFAKKO mice. These data suggest that the myeloid commitment and recruitment of these cells to metastatic sites in RERTFAK<sup>KO</sup> mice are a major driver of the elevated tumour cell colonization observed.

In short, our findings establish a critical mean by which FAK regulates metastasis. Decreasing FAK levels in the stromal and haematopoietic compartment generates a pro-metastatic microenvironment that increases tumour metastasis. Given the importance of understanding the biology behind cancer metastasis, the impact of our study lies in unfolding a mechanism by which FAK in the stromal compartment regulates metastasis.

#### Methods

Mice. FAK<sup>fl/fl</sup> mice<sup>30</sup> were bred with RERTn<sup>ERT/ERT</sup>Cre<sup>31,32</sup> mice provided by **Mice.** FAK<sup>IIII</sup> mice<sup>30</sup> were bred with *RERTn<sup>ERT/ERT</sup>Cre*<sup>31,32</sup> mice provided by Mariano Barbacid to generate  $FAK^{II/I}$  mice that express CreERT2 under the control of the large unit of RNA polymerase 2 (*RERTn<sup>ERT/ERT</sup>Cre*;FAK<sup>II/I</sup>) on a mixed C57BL6/129 background. *RERTn<sup>ERT/ERT</sup>Cre*;FAK<sup>II/I</sup> and control FAK<sup>II/II</sup> mice were bred with *RIP-Tag2* mice<sup>33</sup> provided by Douglas Hanahan generating *RIP-Tag2*;*RERTn<sup>ERT/ERT</sup>Cre*;FAK<sup>II/I</sup> and *RIP-Tag2*;*FAK*<sup>II/II</sup> mice, respectively. WT mice were maintained on a mixed C57/Bl6J/129 background, whereas RIP-Tag2 mice used for transplantation experiments were maintained on a C57/Bl6J background in standard ventilated cages in accordance with CR-UK and QMUL institutional and Home Office guidelines. Male mice were used as bone marrow donors. All experiments were approved by the Animal Research Ethics and United Kingdom Coordination Committee on Cancer Research guidelines and Home Office Regulations.

**RIP-Tag2 model.** RIP-Tag2;RERTn<sup>ERT/ERT</sup>Cre;FAK<sup>fl/fl</sup> and RIP-Tag2;FAK<sup>fl/fl</sup> mice were induced with daily tamoxifen in the chow (Harlan) at 8-9 weeks of age and were culled at 15 weeks of age.

Lethally irradiated *RIP-Tag2* mice were transplanted with bone marrow cells from male *RERTn<sup>ERT/ERT</sup>Cre;FAK<sup>fl/fl</sup>* or *FAK<sup>fl/fl</sup>* control mice at 6 weeks of age. Mice were induced with tamoxifen treatment in the chow at 8-9 weeks of age and were culled at 16 weeks of age.

At necropsy, pancreas with peri-pancreatic lymph nodes, liver and lungs were fixed in 4% formaldehyde in PBS for subsequent immunohistochemical analysis. Invasion grading and metastasis analysis were performed by staining for Tag as described previously<sup>35</sup>. Paraffin-embedded sections of pancreas, liver and lungs were permeabilized in citrate buffer, blocked in 5% normal goat serum, incubated with rabbit anti-mouse large T cell antigen (Santa Cruz Biotechnology) antibody (1:200 dilution) overnight at 4 °C and anti-rabbit biotinylated secondary antibody (1:200 dilution) for 45 min at RT. ABC reagents (Vector Labs) were added and staining developed with DAB (Vector Labs) and couterstained with haematoxylin (Sigma-Aldrich). Five step-wise sections, 100 µm apart were analysed per tissue for all mice.

**Experimental metastasis assays.**  $RERTn^{ERT/ERT}Cre;FAK^{fl/fl}$  or  $RERTn^{ERT/}$ ERTCre control mice were given 3 mg of tamoxifen (Sigma-Aldrich) by gavage for 5 consecutive days and then daily tamoxifen in the chow until the end point of the experiment. Bone marrow transplanted mice were treated with tamoxifen starting 2-3 weeks post transplant. After 5-7 days of tamoxifen treatment,  $0.5 \times 10^6$ tumour cells (B16F0 or B16F10-ATCC, mycoplasma free) resuspended in 100 µl of PBS were injected via the tail vein. Mice were examined for metastases at necropsy. Tissues were either fixed in 4% formaldehyde in PBS or snap-frozen in isopentane cooled in liquid nitrogen for subsequent immunohistochemical analysis.

Bone marrow transplantation. Female mice of at least 6-12 weeks of age were  $\gamma$ -irradiated with 2  $\times$  500 rad doses, 3 h apart, to ablate the endogenous bone marrow. They were immediately rescued by tail vein injection of  $1 \times 10^6$  freshly isolated bone marrow cells from male  $RERTn^{ERT/ERT}Cre;FAK^{fl/fl}$  or  $RERTn^{ERT/}$ enrofloxacin (Baytril, Bayer) until 2 weeks after bone marrow transplantation. RIP-Tag2 mice were transplanted at 6 weeks of age.

Flow cytometry. At different time points, mice were killed and cells isolated from bone marrow, blood, lungs and spleen, and cell surface phenotypes were deter mined by direct immunofluorescence staining with conjugated antibodies for mouse haematopoietic lineage-efluor450 and the anti-mouse antibodies CD117 (c-Kit)-APC, CD135 (Flt3)-PE, CD34-PE, CD16/32-PE-Cy7, CD45-efluor450, Gr1-FITC, Ly6C-APC and CD11b-PE (eBiosciences) and Ly6-A/E (Sca-1)-PerCP-Cy5.5 antibodies (Biolegend) all used at 1:100 dilution. Data were collected and analysed using the BD LSRII and FlowJo softwares.

HSC isolation. HSCs were isolated from lineage depleted or c-Kit-enriched bone marrow as described in refs 67, 68, using Miltenyi magnetic columns separation kits. The cells obtained were then stained with streptavidin PE-Cy7 (Biolegend) (lineage depleted cells) or lineage cocktail antibodies (BD Pharmingen) followed by streptavidin PE-Cy7 (c-Kit-enriched cells) plus anti-mouse c-kit-APC and Ly6-A/E (Sca-1)-Pacific Blue antibodies (Biolegend). Subsequently, Sca1+c-Kit+Lin (HSC) cells were isolated using a fluorescence-activated cell sorting Aria (Becton Dickinson, Franklin Lakes, NJ).

Lung PMN isolation. Single-cell suspensions of lung were obtained by mincing tissue and digesting in HBSS (without Ca, Mg) plus collagenase IV (2 mg ml (Gibco) for 20 min at 37 °C, followed by 5 mM EDTA to stop the reaction and forcing through a 70-µm cell strainer. After lysing the red blood cells and washing in PBS with 2% fetal bovine serum, cells were blocked with Fc block (BD Pharmingen) for 15 min at 4 °C followed by incubation with the following antibody mix: CD45-efluor450, Gr1-FITC, Ly6C-APC and CD11b-PE (eBiosciences). Subsequently, CD45  $^+$  CD11b  $^+$  Gr1^hiLy6C^{lo} (PMN) cells were isolated using a fluorescence-activated cell sorting Aria (Becton Dickinson).

**Gene expression analysis.** RNA was extracted from HSC and PMN using the RNeasy Micro Kit (Qiagen) and recommended protocol. cDNA syntesis was performed in 20–50 ng of RNA using the Sensicript RT Kit (Qiagen) according to manufacturer's instructions. For real time PCR each 20 µl reaction contained test cDNA (1–2 µl), 10 µl Platinum SYBR Green qPCR SuperMix-UDG with Rox (Invitrogen), 300 nM of each forward and reverse primer and nuclease free H<sub>2</sub>O in an individual well of a 96-well plate. The following primer sets were used per reaction: GAPDH fw (5'-CTGCACCAACCAACTGGTTAG-3') and GAPDH rev (5'-GTCTTCTGGGTGGCAGTGAT-3'); FAK fw (5'-AACAGCTATTTGATTTCT TCTCAAAGT-3') and FAK rev (5'-TCTTTTGCTAGATGCTAGGTATCTGT-3'); *PU.1* fw (5'-CGGATGACTTGGTTACTTACG-3') and *PU.1* rev (5'-GTAG-GAAACCTGGTGACTGAG-3')<sup>69</sup>; Gata-1 fw (5'-ATTCCTGGGGGCTCACCTT ATG-3') and Gata-1 rev (5'-TCCAACAGTTCACACACTCTCTGGGC-3')<sup>69</sup>; CXCR4 fw (5'-TCCAACAGGAACCCTGGTTA-3').

The following conditions were used to run the PCR amplification process: 50 °C for 2 mins, denaturation at 95 °C for 10 mins followed by 40 cycles at 95 °C for 15 s and 1 min annealing/extension at 60 °C. Data analyses were accomplished using the StepOne Plus Real Time PCR machine (Applied Biosystems). Data were normalized to endogenous GAPDH and fold changes in gene expression were calculated using the comparative CT method.

**Immunofluorescence.** For immunofluorescence staining for Gr1, 5 µm frozen lung sections were fixed in 100% acetone for 10 min, blocked in 5% normal goat serum (Sigma-Aldrich) for 1 h, incubated with rat anti-Gr1 (clone RB6-8C5—BD Pharmingen) primary antibody (1:50 dilution) overnight at 4 °C and anti-rat Alexa-Fluor-488 (Molecular Probes) secondary antibody (1:200 dilution) for 45 min at room temperature and finally mounted with Prolong anti-fade with 4',6-diamidino-2-phenylindole (DAPI; Molecular Probes). Gr1 <sup>+</sup> cell numbers were quantified microscopically in at least five different fields per section. Values are given relative to total number of cells as assessed by the DAPI signal.

**Cytokine analysis in serum.** At indicated time points mice were killed, blood collected by heart puncture, left to clot for 2 h at room temperature and centrifuged at 2,000 g for 20 min. Mouse cytokine arrays (Proteome Profiller ARY006—R&D Systems) were processed according to manufacturer's instructions using 100  $\mu$ l of serum per membrane. Pixel analysis was used for quantification using Image J software.

In vivo homing/colonization assays. B16F0 cells, previously labelled with red cell tracker CMTPX (Molecular probes, Invitrogen, Life Sciences), were resuspended at  $0.5 \times 10^6$  cells per 100 µl of PBS and injected via the tail vein into mice. At 2 or 48 h post inoculation, mice were killed and lungs fixed in 4% paraformaldehyde. Lungs were dissected, photographed using a Leica MZ16F fluorescence stereomicroscope, snap-frozen in OCT (OCT Killik, Bio-Optica, IT) and 5 µm cryosections were prepared for analysis. Total numbers of red fluorescent tumour cells were quantified and normalized for the total number of DAPI-positive nuclei for each section using a Zeiss Axioplan microscope (Zeiss).

**Gr1 depletion experiments.** Mice were given 50  $\mu$ g of rat anti-mouse Gr1 antibody (RB6-8C5, eBiosciences) or rat anti-mouse IgG2b  $\kappa$  isotype control antibody (eBiosciences) in 100  $\mu$ l PBS one day before and on the day of tumour cell injection. Homing/colonization assays were performed as described in the *In vivo* homing/ colonization assays section.

**CXCR4 inhibition experiments.** Mice were given  $5 \text{ mg kg}^{-1}$  of AMD3100 (Sigma) or PBS intraperitoneal on the day of tumour cell injection and following days until harvesting. Homing/colonization assays were performed as described in the *In vivo* homing/colonization assays section. At 48 h time point mice were harvested within 60–90 min after inhibitor treatment.

**Statistical analysis.** Results are presented as means ± standard error of the mean (s.e.m.) for at least 2–3 independent experiments, unless otherwise stated. The sample sizes used were based on level of changes and consistency expected. Statistical significance was reported as appropriate. Experimental metastasis and *RIP-Tag2* data analysis of statistical significance was performed using nonparametric Mann–Whitney and  $\chi^2$  tests. All other data sets were analysed for statistical significant. Sample sizes were chosen on the basis of the level of changes expected. No randomization methods were used. During animal experiments, the investigator was blinded to the genotype of the animals under study.

#### References

- Schaller, M. D. et al. pp125FAK a structurally distinctive protein-tyrosine kinase associated with focal adhesions. Proc. Nat. Acad. Sci. USA 89, 5192–5196 (1992).
- 2. Sieg, D. J. *et al.* FAK integrates growth-factor and integrin signals to promote cell migration. *Nat. Cell Biol.* **2**, 249–256 (2000).
- Golubovskaya, V., Kaur, A. & Cance, W. Cloning and characterization of the promoter region of human focal adhesion kinase gene: nuclear factor kappa B and p53 binding sites. *Biochim. Biophys. Acta* 1678, 111–125 (2004).
- Cance, W. G. *et al.* Immunohistochemical analyses of focal adhesion kinase expression in benign and malignant human breast and colon tissues: correlation with preinvasive and invasive phenotypes. *Clin. Cancer Res.* 6, 2417–2423 (2000).
- de Heer, P. et al. Combined expression of the non-receptor protein tyrosine kinases FAK and Src in primary colorectal cancer is associated with tumor recurrence and metastasis formation. Eur. J. Surg. Oncol. 34, 1253–1261 (2008).
- de Vicente, J. C. et al. Focal adhesion kinase overexpression: Correlation with lymph node metastasis and shorter survival in oral squamous cell carcinoma. *Head Neck* 35, 826–830 (2012).
- Cai, L. *et al.* Overexpression and significance of focal adhesion kinase in hepatocellular carcinoma and its relationship with HBV infection. *Med. Oncol.* 26, 409–414 (2009).
- Park, J. H. et al. Focal adhesion kinase (FAK) gene amplification and its clinical implications in gastric cancer. Hum. Pathol. 41, 1664–1673 (2010).
- Stokes, J. B. *et al.* Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment. *Mol. Cancer Ther.* 10, 2135–2145 (2011).
- Kurio, N. et al. Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo. Exp. Cell Res. 317, 1134–1146 (2011).
- Walsh, C. *et al.* Oral delivery of PND-1186 FAK inhibitor decreases tumor growth and spontaneous breast to lung metastasis in pre-clinical models. *Cancer Biol. Ther.* 9, 778–790 (2010).
- Gabriel, B. *et al.* Weak expression of focal adhesion kinase (pp125FAK) in patients with cervical cancer is associated with poor disease outcome. *Clin. Cancer Res.* 12, 2476–2483 (2006).
- Zheng, Y. *et al.* FAK phosphorylation by ERK primes ras-induced tyrosine dephosphorylation of FAK mediated by PIN1 and PTP-PEST. *Mol. Cell* 35, 11–25 (2009).
- 14. Joyce, J. A. & Pollard, J. W. Microenvironmental regulation of metastasis. *Nat. Rev. Cancer* **9**, 239–252 (2009).
- Paget, S. The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8, 98–101 (1989).
- Malanchi, I. *et al.* Interactions between cancer stem cells and their niche govern metastatic colonization. *Nature* 481, 85–89 (2012).
- Du, R. *et al.* HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. *Cancer Cell* 13, 206–220 (2008).
- Kaplan, R. N. et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 438, 820–827 (2005).
- Diaz-Montero, C. M. *et al.* Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. *Cancer Immunol. Immunother.* 58, 49–59 (2009).
- Almand, B. *et al.* Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. *J. Immunol.* 166, 678–689 (2001).
- Gabrilovich, D. I. & Nagaraj, S. Myeloid-derived suppressor cells as regulators of the immune system. *Nat. Rev. Immunol.* 9, 162–174 (2009).
- Ostrand-Rosenberg, S. & Sinha, P. Myeloid-derived suppressor cells: linking inflammation and cancer. J. Immunol. 182, 4499–4506 (2009).
- Connolly, M. K. *et al.* Distinct populations of metastases-enabling myeloid cells expand in the liver of mice harboring invasive and preinvasive intra-abdominal tumor. *J. Leukoc. Biol.* 87, 713–725 (2010).
- Sceneay, J. et al. Primary tumor hypoxia recruits CD11b + /Ly6Cmed/Ly6G + immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res. 72, 3906–3911 (2012).
- Yang, L. *et al.* Abrogation of TGF beta signaling in mammary carcinomas recruits Gr-1+CD11b + myeloid cells that promote metastasis. *Cancer Cell* 13, 23–35 (2008).
- 26. Yan, H. H. *et al.* Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung. *Cancer Res.* 70, 6139–6149 (2010).
- Spicer, J. D. et al. Neutrophils promote liver metastasis via Mac-1 mediated interactions with circulating tumor cells. *Cancer Res.* 72, 3919–3927 (2012).
- Huh, S. J., Liang, S., Sharma, A., Dong, C. & Robertson, G. P. Transiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis development. *Cancer Res.* **70**, 6071–6082 (2010).
- Qian, B. Z. et al. CCL2 recruits inflammatory monocytes to facilitate breasttumour metastasis. Nature 475, 222–225 (2011).

NATURE COMMUNICATIONS | 5:5054 | DOI: 10.1038/ncomms6054 | www.nature.com/naturecommunications

### ARTICLE

- McLean, G. W. *et al.* Specific deletion of focal adhesion kinase suppresses tumor formation and blocks malignant progression. *Genes Dev.* 18, 2998–3003 (2004).
- Guerra, C. et al. Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell 4, 111–120 (2003).
- 32. Barriere, C. et al. Mice thrive without Cdk4 and Cdk2. Mol. Oncol. 1, 72–83 (2007).
- Hanahan, D. Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. *Nature* 315, 115–122 (1985).
- 34. Lopez, T. & Hanahan, D. Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. *Cancer Cell* 1, 339–353 (2002).
- Paez-Ribes, M. *et al.* Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. *Cancer Cell* 15, 220–231 (2009).
- 36. Hiratsuka, S., Watanabe, A., Aburatani, H. & Maru, Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. *Nat. Cell Biol.* 8, 1369–1375 (2006).
- De Palma, M. *et al.* Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. *Cancer Cell* 8, 211–226 (2005).
- Catena, R. et al. Bone marrow-derived Gr1+ cells can generate a metastasisresistant microenvironment via induced secretion of thrombospondin-1. *Cancer Discov.* 3, 578–589 (2013).
- Avraham, H., Park, S. Y., Schinkmann, K. & Avraham, S. RAFTK/Pyk2mediated cellular signalling. *Cell. Signal.* 12, 123–133 (2000).
- Weis, S. M. *et al.* Compensatory role for Pyk2 during angiogenesis in adult mice lacking endothelial cell FAK. *J. Cell Biol.* 181, 43–50 (2008).
- Avraham, S. *et al.* Identification and characterization of a novel related adhesion focal tyrosine kinase (RAFTK) from megakaryocytes and brain. *J. Biol. Chem.* 270, 27742–27751 (1995).
- Lu, J. *et al.* Fak depletion in both hematopoietic and nonhematopoietic niche cells leads to hematopoietic stem cell expansion. *Exp. Hematol.* 40, 307–317.e3 (2012).
- Fleming, H. E. *et al.* Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. *Cell Stem Cell* 2, 274–283 (2008).
- Scott, E. W., Simon, M. C., Anastasi, J. & Singh, H. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. *Science* 265, 1573–1577 (1994).
- Tenen, D. G., Hromas, R., Licht, J. D. & Zhang, D. E. Transcription factors, normal myeloid development, and leukemia. *Blood* 90, 489–519 (1997).
- Visvader, J. E., Elefanty, A. G., Strasser, A. & Adams, J. M. GATA-1 but not SCL induces megakaryocytic differentiation in an early myeloid line. *EMBO J.* 11, 4557–4564 (1992).
- Kulessa, H., Frampton, J. & Graf, T. GATA-1 reprograms avian myelomonocytic cell lines into eosinophils, thromboblasts, and erythroblasts. *Genes Dev.* 9, 1250–1262 (1995).
- Wright, D. E., Wagers, A. J., Gulati, A. P., Johnson, F. L. & Weissman, I. L. Physiological migration of hematopoietic stem and progenitor cells. *Science* 294, 1933–1936 (2001).
- Bhattacharya, D., Bryder, D., Rossi, D. J. & Weissman, I. L. Rapid lymphocyte reconstitution of unconditioned immunodeficient mice with non-self-renewing multipotent hematopoietic progenitors. *Cell Cycle* 5, 1135–1139 (2006).
- Gil, M., Seshadri, M., Komorowski, M. P., Abrams, S. I. & Kozbor, D. Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases. *Proc. Natl Acad. Sci. USA* 110, E1291–E1300 (2013).
- Jablonska, J., Leschner, S., Westphal, K., Lienenklaus, S. & Weiss, S. Neutrophils responsive to endogenous IFN-beta regulate tumor angiogenesis and growth in a mouse tumor model. J. Clin. Invest. 120, 1151–1164 (2010).
- Fleming, S. D., Anderson, J., Wilson, F., Shea-Donohue, T. & Tsokos, G. C. C5 is required for CD49d expression on neutrophils and VCAM expression on vascular endothelial cells following mesenteric ischemia/reperfusion. *Clin. Immunol.* **106**, 55–64 (2003).
- Corrales, L. *et al.* Anaphylatoxin C5a creates a favorable microenvironment for lung cancer progression. *J. Immunol.* 189, 4674–4683 (2012).
- 54. Hauck, C. R. et al. Inhibition of focal adhesion kinase expression or activity disrupts epidermal growth factor-stimulated signaling promoting the migration of invasive human carcinoma cells. *Cancer Res.* 61, 7079–7090 (2001).
- 55. Mitra, S. K., Lim, S. T., Chi, A. & Schlaepfer, D. D. Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngeneic tumor model. *Oncogene* 25, 4429–4440 (2006).
- Theocharis, S. E. et al. Focal adhesion kinase expression is not a prognostic predictor in colon adenocarcinoma patients. Eur. J. Surg. Oncol. 29, 571–574 (2003).

- Desgrosellier, J. S. *et al.* An integrin alpha(v)beta(3)-c-Src oncogenic unit promotes anchorage-independence and tumor progression. *Nat. Med.* 15, 1163–1169 (2009).
- Becker, A. J., Mc, C. E. & Till, J. E. Cytological demonstration of the clonal nature of spleen colonies derived from transplanted mouse marrow cells. *Nature* 197, 452–454 (1963).
- 59. Till, J. E. & Mc, C. E. A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. *Radiat. Res.* 14, 213–222 (1961).
- Mercier, F. E., Ragu, C. & Scadden, D. T. The bone marrow at the crossroads of blood and immunity. *Nat. Rev. Immunol.* 12, 49–60 (2012).
- Wilson, A. *et al.* Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. *Cell* 135, 1118–1129 (2008).
- Cheshier, S. H., Morrison, S. J., Liao, X. & Weissman, I. L. In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. *Proc. Natl Acad. Sci. USA* 96, 3120–3125 (1999).
- Lim, S. T. et al. Nuclear-localized focal adhesion kinase regulates inflammatory VCAM-1 expression. J. Cell Biol. 197, 907–919 (2012).
- Migliaccio, A. R. et al. Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease. Exp. Hematol. 36, 158–171 (2008).
- Gipson, T. S. et al. Regulatory effects of endogenous protease inhibitors in acute lung inflammatory injury. J. Immunol. 162, 3653–3662 (1999).
- Markiewski, M. M. et al. Modulation of the antitumor immune response by complement. Nat. Immunol. 9, 1225–1235 (2008).
- Carlson, A. L. *et al.* Tracking single cells in live animals using a photoconvertible near-infrared cell membrane label. *PLoS ONE* 8, e69257 (2013).
- Lam, B. S., Cunningham, C. & Adams, G. B. Pharmacologic modulation of the calcium-sensing receptor enhances hematopoietic stem cell lodgment in the adult bone marrow. *Blood* 117, 1167–1175 (2011).
- Yoshida, T., Ng, S. Y., Zuniga-Pflucker, J. C. & Georgopoulos, K. Early hematopoietic lineage restrictions directed by Ikaros. *Nat. Immunol.* 7, 382–391 (2006).

#### Acknowledgements

We thank Julie Holdsworth (Bart Cancer Institute, QMUL, UK), Bruce Williams (Cancer Research UK), Garry Saunders (Cancer Research UK), Colin Wren (Cancer Research UK) and Colin Pegrum (Cancer Research UK) for their technical help with animal experiments; Stephen Robinson (University of East Anglia, UK) for initial contributions to the project; Daniela Taverna (University of Turin, Italy) for advice on homing experiments and Guglielmo Rosignoli (Bart Cancer Institute, QMUL, UK) and Catherine Simpson (Imperial College, UK) for flow cytometry expertise. This work was supported by grants from Cancer Research UK (C82181/A12007), Breast Cancer Campaign (2010MayPR39), Association of International Cancer Research (12-1068) and The Medical Research Council (G0901609). Part of this work was also supported by Cancer Research UK (C18270/A12888 and C18270/A14355) to T.H., Pancreatic Cancer Research Fund (T.H.), People Programme (Marie Curie Actions) of the European Union's Seventh Framework Programme FP7/2007-2013 under REA grant agreement no. 317445 (T.H.).

#### Author contributions

The following authors are listed in the author list in alphabetical order: E.M. and L.E.R. for their equal and combined contribution to the paper. S.B. and K.H.-D. designed the experiments; S.B. performed the experiments. E.M. performed some of the granulocyte and monocyte flow cytometry data; L.E.R. performed some of the Gr1 rescue and prosaposin experiments *in vivo* and also whole-kidney FAK and some of the Tsp-1 analysis by western blot; B.T. performed some of the *RIP-Tag2* harvesting and treatment experiments; D.M.L. helped in the focal contact protein western blot; I.F. helped in the cytokine arrays; G.E. carried out the histology; O.C. provided advice in histological analysis of invasion and metastasis in the *RIP-Tag2* model; C.L.C. provided advice in the HSC sorting and haematopoietic progenitor analysis by flow cytometry; T.H. provided advice on immunologic analysis by flow cytometry. S.B. and K.H.-D. wrote the paper with substantial input from the co-authors.

#### Additional information

Supplementary Information accompanies this paper at http://www.nature.com/ naturecommunications

Competing financial interests: The authors declare no competing financial interests.

Reprints and permission information is available online at http://npg.nature.com/ reprintsandpermissions/

How to cite this article: Batista, S. *et al.* Haematopoietic focal adhesion kinase deficiency alters hematopoietic homeostasis to drive tumour metastasis. *Nat. Commun.* 5:5054 doi: 10.1038/ncomms6054 (2014).